GlaxoSmithKline's shingles vaccine a step closer to possible FDA approval

Josh White Sharecast | 14 Sep, 2017 08:06 | | |

gsk-fait-legerement-mieux-qu-attendu
  • 1,468.00
  • 0.96%14.00
  • Max: 1,471.50
  • Min: 1,455.50
  • Volume: 5,856,549
  • MM 200 : n/a
17:05 21/09/17
  • 7,266.87
  • -0.07%-5.08
  • Max: 7,289.16
  • Min: 7,260.05
  • Volume: 0
  • MM 200 : n/a
16:45 21/09/17
  • 3,414.44
  • -0.37%-12.67
  • Max: 3,429.40
  • Min: 3,411.14
  • Volume: 0
  • MM 200 : n/a
17:05 21/09/17
  • 1,505.06
  • 0.40%5.97
  • Max: 1,507.01
  • Min: 1,501.15
  • Volume: 0
  • MM 200 : n/a
16:50 21/09/17
  • 12,844.24
  • 0.47%60.03
  • Max: 12,879.13
  • Min: 12,784.21
  • Volume: 0
  • MM 200 : n/a
17:05 21/09/17
  • 4,035.42
  • -0.20%-8.03
  • Max: 4,048.50
  • Min: 4,033.21
  • Volume: 0
  • MM 200 : n/a
17:05 21/09/17
  • 3,986.18
  • -0.17%-6.75
  • Max: 3,997.75
  • Min: 3,982.99
  • Volume: 0
  • MM 200 : n/a
16:50 21/09/17

GlaxoSmithKline announced on Thursday that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the US Food and Drug Administration voted unanimously that its data supported the efficacy and safety of its ‘Shingrix’ product, for the prevention of herpes zoster (shingles) in adults ages 50 and over.

The FTSE 100 drugmaker said the FDA Advisory Committees provide non-binding recommendations for consideration by the FDA, with the final decision on approval made by the administration itself.

“Shingles is a painful and potentially serious condition,” said GSK’s senior vice president and head of vaccines Dr Emmanuel Hanon.

“The risk of developing shingles increases with age and it is estimated that up to one in three people in the United States will develop shingles.

“Today's vote brings us one step closer to approval of Shingrix, which is specifically designed to overcome age-related weakening of the immune system.”

The Biologics License Application (BLA) was submitted to the FDA in October 2016.

GSK said its shingles candidate vaccine was not currently approved for use anywhere in the world, although regulatory filings in the European Union, Canada, Australia and Japan were also underway.

It said the candidate vaccine is a non-live, recombinant subunit vaccine to help prevent herpes zoster (shingles) and its complications, such as postherpetic neuralgia, in adults 50 years of age and older.

“The candidate vaccine combines an antigen, glycoprotein E, and an adjuvant system, AS01B, intended to generate a strong and long-lasting immune response that can help overcome the decline in immunity as people age,” the GSK board said.

“The name ‘Shingrix’ has not yet been approved for use by any regulatory authority.”

More news

17:02 Capita dives despite making progress in first half, results 'difficult to read'

Capita reported a mixed set of results for the first six months of the year but said underlying profits would "rise modestly" in the second half compared to the first, though some investors and analysts found the numbers rather disappointing and difficult to decode.

16:58 Capita staff prepare for strikes over pensions

Alongside Capita's labyrinthine half-year results that left many investors cold and sent the shares down 11%, the company was also forced to prepare for industrial action after unions voted to strike.

16:53 Chevron cancels drillship contract with Transocean

Chevron blew a hole in Transocean's share price on Thursday after cancelling its contract for ultra-deep water drillship Discoverer Clear Leader one year ahead of its scheduled expiry, effective from the following November.

16:21 Barnier fires shot across May's bows ahead of Florence speech

Ahead of the UK Prime Minister's major Brexit speech on Friday, chief European Union Brexit negotiator Michel Barnier has warned Theresa May against trying to have her cake and eat it and stressing that if a transition period is requested it will first require a withdrawal agreement.

16:16 US open: Stocks dip as two-year yields hover near eight-year highs

Stocks are stuck in a bit of a rut as traders try to work out the implications of the US central bank's policy announcement the night before, despite a raft of better-than-expected readings on the economy.

15:54 IG Design Group swallows Aussie card firm Biscay

Designer and manufacturer of celebration, gifting, stationery and creative play products IG Design Group announced on Thursday that it has signed a contract to acquire the trade and certain assets of Biscay Greetings, which it described as a “leading” greetings card and paper products business based in Australia.

15:54 Friday preview: Importance of May's Brexit speech 'cannot be over-emphasised'

Theresa May's Big Brexit Speech in Florence may dominate the narrative on Friday, though for traders and investors there's PMI surveys and one from the CBI, with results from Sage and Smiths Group.

15:52 Engineering studies to enable Liberator field begin, i3 says

Independent oil and gas company i3 Energy announced on Thursday that detailed engineering studies to enable its 100% owned-and-operated Liberator field, to be tied into the existing Blake field 'host' infrastructure and produced through the Bleo Holm floating production storage and offloading vessel (FPSO) had commenced.

15:50 FTSE 250 movers: Kier rallies on results but Capita crumbles

London's FTSE 250 was down 0.6% to 19,422.90 in afternoon trade on Thursday.

15:39 Eurozone consumer confidence increases in September

Eurozone households are feeling more confident about the economic situation, according to a key European Commission survey released on Thursday afternoon.